Answer
Yes, when specified in the indication, selection for Keytruda (pembrolizumab) treatment based on MSI-H/dMMR tumour status should be confirmed by a validated test.
Sources for this answer
- KEYTRUDA 25 mg/mL concentrate for solution for infusionMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.2 Posology and method of administration · Version 64Document updated
Sources checked